Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors

Stopped early · Phase 1/Phase 2

Conditions studied: Growth Hormone Deficiency

In brief

The purpose of this study is to see if giving growth hormone or insulin-like growth factor-1 (IGF-1) to subjects with growth hormone deficiency effects cardiovascular risk factors differently.

Key facts

Study ID

NCT00684957

Run by

Columbia University

People needed

5

Starts

2008-01-01

Expected to finish

2012-10-01

Last updated by the study team

2024-07-17

Who can join

Age: 25 and older, up to 65. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Adult male age 25-65 with documented growth hormone deficiency on stable doses x 3 months (at least) of any hormone replacement therapies and with stable MRIs x 2 years in the setting of a known pituitary mass.

You may not qualify if…

• Female gender
• current GH use or GH use within three months of the study
• diabetes
• hypoglycemia
• liver or kidney disease
• use of drugs that could increase GH secretion (i.e. L-dopa)
• alcohol or substance abuse
• use of investigational drugs within four weeks of our study and use of supraphysiologic doses of steroids within the previous six months.

Where it is running

• Columbia University, College of Physicians and Surgeons — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.